Patents by Inventor Joachim BOUCNEAU
Joachim BOUCNEAU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240141030Abstract: VEGF-binding molecules, preferably VEGF-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF-mediated effects on angiogenesis. Nucleic acids encoding VEGF-binding molecules, host cells and methods for preparing same.Type: ApplicationFiled: January 11, 2024Publication date: May 2, 2024Inventors: Andreas GSCHWIND, Eric BORGES, Joachim BOUCNEAU, Evelyn DE TAVERNIER, Joost KOLKMAN, Pascal MERCHIERS
-
Publication number: 20230203146Abstract: Ang2-binding molecules, preferably Ang2-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with Ang2-mediated effects on angiogenesis. Nucleic acids encoding Ang2-binding molecules, host cells and methods for preparing same.Type: ApplicationFiled: March 17, 2023Publication date: June 29, 2023Inventors: Rene Georg OTT, Eric BORGES, Andreas GSCHWIND, Joachim BOUCNEAU, Marie-Ange BUYSE, Erik DEPLA, Pascal MERCHIERS, Frederik STEVENAERT
-
Publication number: 20220363744Abstract: VEGF-binding molecules, preferably VEGF-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF-mediated effects on angiogenesis. Nucleic acids encoding VEGF-binding molecules, host cells and methods for preparing same.Type: ApplicationFiled: June 21, 2022Publication date: November 17, 2022Inventors: Andreas GSCHWIND, Eric BORGES, Joachim BOUCNEAU, Evelyn DE TAVERNIER, Joost KOLKMAN, Pascal MERCHIERS
-
Publication number: 20220017642Abstract: Bispecifc binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.Type: ApplicationFiled: September 27, 2021Publication date: January 20, 2022Inventors: Andreas GSCHWIND, Rene Georg OTT, Joachim BOUCNEAU, Marie-Ange BUYSE, Erik DEPLA
-
Patent number: 11161916Abstract: Bispecifc binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.Type: GrantFiled: July 18, 2019Date of Patent: November 2, 2021Assignee: Boehringer Ingelheim International GmbHInventors: Andreas Gschwind, Rene Georg Ott, Joachim Boucneau, Marie-Ange Buyse, Erik Depla
-
Publication number: 20200308267Abstract: VEGF-binding molecules, preferably VEGF-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF-mediated effects on angiogenesis. Nucleic acids encoding VEGF-binding molecules, host cells and methods for preparing same.Type: ApplicationFiled: June 17, 2020Publication date: October 1, 2020Inventors: Andreas GSCHWIND, Eric BORGES, Joachim BOUCNEAU, Evelyn DE TAVERNIER, Joost KOLKMAN, Pascal MERCHIERS
-
Publication number: 20200207845Abstract: Ang2-binding molecules, preferably Ang2-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with Ang2-mediated effects on angiogenesis. Nucleic acids encoding Ang2-binding molecules, host cells and methods for preparing same.Type: ApplicationFiled: March 13, 2020Publication date: July 2, 2020Inventors: Rene Georg Ott, Eric Borges, Andreas Gschwind, Joachim Boucneau, Marie-Ange Buyse, Erik Depla, Pascal Merchiers, Frederik Stevenaert
-
Patent number: 10544211Abstract: The present invention relates to amino acid sequences, compounds and polypeptides binding to tumor necrosis factor alpha (“TNF” or “TNF-alpha”). In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVDs”) binding to tumor necrosis factor alpha, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs, collectively TNF binders. Other aspects, embodiments, features, uses and advantages of the invention will be clear to the skilled person based on the disclosure herein.Type: GrantFiled: November 14, 2016Date of Patent: January 28, 2020Assignee: Ablynx N.V.Inventors: Marie-Ange Buyse, Joachim Boucneau, Peter Casteels, Gino Van Heeke
-
Publication number: 20200010569Abstract: Bispecific binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.Type: ApplicationFiled: July 18, 2019Publication date: January 9, 2020Inventors: Andreas GSCHWIND, Rene Georg OTT, Joachim BOUCNEAU, Marie-Ange BUYSE, Erik DEPLA
-
Patent number: 10414828Abstract: Bispecific binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.Type: GrantFiled: November 14, 2016Date of Patent: September 17, 2019Assignee: Boehringer Ingelheim International GmbHInventors: Andreas Gschwind, Rene Georg Ott, Joachim Boucneau, Marie-Ange Buyse, Erik Depla
-
Publication number: 20190135907Abstract: Ang2-binding molecules, preferably Ang2-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with Ang2-mediated effects on angiogenesis. Nucleic acids encoding Ang2-binding molecules, host cells and methods for preparing same.Type: ApplicationFiled: July 2, 2018Publication date: May 9, 2019Inventors: Rene Georg Ott, Eric Borges, Andreas Gschwind, Joachim Boucneau, Marie-Ange Buyse, Erik Depla, Pascal Merchiers, Frederik Stevenaert
-
Publication number: 20180201671Abstract: VEGF-binding molecules, preferably VEGF-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF-mediated effects on angiogenesis. Nucleic acids encoding VEGF-binding molecules, host cells and methods for preparing same.Type: ApplicationFiled: December 5, 2017Publication date: July 19, 2018Inventors: Andreas GSCHWIND, Eric BORGES, Joachim BOUCNEAU, Evelyn DE TAVERNIER, Joost KOLKMAN, Pascal MERCHIERS
-
Publication number: 20170267752Abstract: The present invention relates to amino acid sequences, compounds and polypeptides binding to tumor necrosis factor alpha (“TNF” or “TNF-alpha”). In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVDs”) binding to tumor necrosis factor alpha, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs, collectively TNF binders. Other aspects, embodiments, features, uses and advantages of the invention will be clear to the skilled person based on the disclosure herein.Type: ApplicationFiled: November 14, 2016Publication date: September 21, 2017Applicant: Ablynx N.V.Inventors: Marie-Ange Buyse, Joachim Boucneau, Peter Casteels, Gino Van Heeke
-
Publication number: 20170247475Abstract: Bispecifc binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.Type: ApplicationFiled: November 14, 2016Publication date: August 31, 2017Inventors: Andreas GSCHWIND, Rene Georg OTT, Joachim BOUCNEAU, Marie-Ange BUYSE, Erik DEPLA
-
Patent number: 9745372Abstract: The present invention relates to amino acid sequences, compounds and polypeptides binding to tumor necrosis factor alpha (“TNF” or “TNF-alpha”). In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVDs”) binding to tumor necrosis factor alpha, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs, collectively TNF binders. Other aspects, embodiments, features, uses and advantages of the invention will be clear to the skilled person based on the disclosure herein.Type: GrantFiled: March 13, 2017Date of Patent: August 29, 2017Assignee: Ablynx N.V.Inventors: Marie-Ange Buyse, Joachim Boucneau, Peter Casteels, Gino Van Heeke
-
Publication number: 20170190769Abstract: The present invention relates to amino acid sequences, compounds and polypeptides binding to tumor necrosis factor alpha (“TNF” or “TNF-alpha”). In particular, the present invention relates to improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISV's” or “ISVDs”) binding to tumor necrosis factor alpha, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs, collectively TNF binders. Other aspects, embodiments, features, uses and advantages of the invention will be clear to the skilled person based on the disclosure herein.Type: ApplicationFiled: March 13, 2017Publication date: July 6, 2017Applicant: Ablynx N.V.Inventors: MARIE-ANGE Buyse, Joachim Boucneau, Peter Casteels, Gino Van Heeke
-
Publication number: 20170107281Abstract: Ang2-binding molecules, preferably Ang2-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with Ang2-mediated effects on angiogenesis. Nucleic acids encoding Ang2-binding molecules, host cells and methods for preparing same.Type: ApplicationFiled: December 21, 2016Publication date: April 20, 2017Applicant: Boehringer Ingelheim International GmbHInventors: Rene Georg OTT, Eric BORGES, Andreas GSCHWIND, Joachim BOUCNEAU, Marie-Ange BUYSE, Erik DEPLA, Pascal MERCHIERS, Frederik STEVENAERT
-
Patent number: 9527925Abstract: Bispecific binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.Type: GrantFiled: March 29, 2012Date of Patent: December 27, 2016Assignee: Boehringer Ingelheim International GmbHInventors: Andreas Gschwind, Rene Georg Ott, Joachim Boucneau, Marie-Ange Buyse, Erik Depla
-
Publication number: 20160200806Abstract: VEGF-binding molecules, preferably VEGF-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF-mediated effects on angiogenesis. Nucleic acids encoding VEGF-binding molecules, host cells and methods for preparing same.Type: ApplicationFiled: December 18, 2015Publication date: July 14, 2016Inventors: Andreas GSCHWIND, Eric BORGES, Joachim BOUCNEAU, Evelyn DE TAVERNIER, Joost KOLKMAN, Pascal MERCHIERS
-
Publication number: 20140120095Abstract: Bispecific binding molecules, in particular immunoglobulin single variable domains such as VHHs and domain antibodies, comprising a VEGF-binding component and a DII4-binding component in one molecule. Pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF- and DII4-mediated effects on angiogenesis. Nucleic acids encoding the bispecific binding molecules, host cells and methods for preparing same.Type: ApplicationFiled: March 22, 2013Publication date: May 1, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Eric BORGES, Andreas GSCHWIND, Joachim BOUCNEAU, Evelyn DE TAVERNIER, Joost KOLKMAN, Pascal MERCHIERS, Diane VAN HOORICK